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The lipase inhibitor, orlistat, is used in the treatment of obesity and reduces fat absorption by about 30%. However, the mean weight loss
induced by orlistat is less than expected for the degree of fat malabsorption. It was hypothesised that lipase inhibition with orlistat attenu-
ates the suppressive effects of oral fat on subsequent energy intake in normal-weight subjects. Fourteen healthy, lean subjects (nine males,
ﬁve females; aged 25^1·3 years) were studied twice, in a double-blind fashion. The subjects received a high-fat yoghurt ‘preload’ (males
400g (2562kJ); females 300g (1923kJ)), containing orlistat (120mg) on one study day (and no orlistat on the other ‘control’ day), 30min
before ad libitum access to food and drinks; energy intake was assessed during the following 8h. Blood samples were taken at regular
intervals for the measurement of plasma cholecystokinin (CCK). Each subject performed a 3d faecal fat collection following each
study. Energy intake during the day was greater following orlistat (10220 (SEM 928) kJ) v. control (9405 (SEM 824) kJ) (P¼0·02). On
both days plasma CCK increased (P,0·05) after the preload. Plasma CCK 20min following ingestion of the preload was less after orlistat
(4·1 (SEM 0·9) pmol/l) v. control (5·3 (SEM 0·9) pmol/l (P¼0·028); however there was no difference in the area under the curve 0–510min
between the two study days. Fat excretion was greater following orlistat (1017 (SEM 168) kJ) v. control (484 (SEM 90) kJ) (P¼0·004). In
conclusion, in healthy, lean subjects the acute inhibitory effect of fat on subsequent energy intake is attenuated by orlistat and the increase
in energy intake approximates the energy lost due to fat malabsorption.
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The lipase inhibitor tetrahydrolipstatin, or orlistat, is used
widely in the treatment of obesity and, when given in a
dose of 120mg three times daily, decreases fat absorption
by approximately 30% (Zhi et al. 1994). Although the
malabsorptive potency of orlistat is maintained with
chronic use, the mean weight loss achieved is less than
would be predicted by the degree of fat malabsorption
(Hill et al. 1999; Kline, 1999), suggesting that some
patients taking orlistat may increase their energy intake.
There is also substantial variation in the extent of weight
loss between individuals with some subjects gaining
weight (Hill et al. 1999).
In healthy lean and obese subjects both oral and duode-
nal administration of fat suppresses hunger and decreases
subsequent energy intake (Read et al. 1994; Chapman
et al. 1999). These effects are known to be dependent on
the hydrolysis of triacylglycerols to non-esteriﬁed fatty
acids by lipase (Feinle et al. 2003) and may be medi-
ated by cholecystokinin (CCK) (Matzinger et al. 2000;
Beglinger et al. 2001) and other gut peptides including
glucagon-like peptide-1 (Feinle et al. 2003). It has been
demonstrated in healthy lean men that acute lipase inhi-
bition with 120mg orlistat attenuates the inhibitory effects
of a duodenal fat infusion on appetite, as assessed at a
buffet meal, as well as the CCK response (Feinle et al.
2003). The acute effects of orlistat on appetite following
an oral fat load have not been evaluated, and this would
help to clarify if subsequent energy intake is increased.
The present study was designed to address the hypothesis
that lipase inhibition by orlistat attenuates the suppressive




Fourteen healthy subjects (nine male, ﬁve female) were
recruited by advertisements in local newspapers. The sub-
jects had a mean age of 25^1·3 years and were all of
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2). All
subjects completed a number of questionnaires to assess
eating habits. Questionnaires completed were the restraint
section of the three-factor eating questionnaire which
measures dietary restraint (Stunkard & Messick, 1985)
(possible score 0–18), the Eating Attitudes Test which
detects aberrant attitudes towards food and eating
(Garner et al. 1982) (possible score 0–140), and the
Zung self-rating questionnaire which detects depression
(Zung et al. 1965) (possible score 20–80). Exclusion
criteria included evidence of dietary restraint (score .12
on the three-factor eating questionnaire, restraint section),
an eating disorder (score $30 on the Eating Attitudes
Test) or depression (score $40 on the Zung self-rating
depression scale). In addition, subjects on medication that
could affect appetite, body weight or gastrointestinal func-
tion or with a history of gastrointestinal disease or surgery,
had an alcohol consumption of .20g/d or who were
smokers, were also excluded. The study protocol, which
conformed to the standards set by the Declaration of Hel-
sinki, was approved by the Ethics Committee of the
Royal Adelaide Hospital, and each subject gave written
informed consent before inclusion. To minimise the possi-
bility of experimental bias subjects were informed that the
main purpose of the study was to assess the effect of fat on
hormone secretion. The subjects received an honorarium
for participation in the study.
Study design
Paired studies, separated by 7–9d, were performed in a
randomised, double-blind fashion. Each subject attended
the laboratory after an overnight fast and at 09.00 hours
was given a high-fat (70% energy from fat) yoghurt ‘pre-
load’ (males 400g (2562kJ); females 300g (1923kJ)),
which included 120mg orlistat (Xenical
w; Hoffmann-La
Roche, Basle, Switzerland) on one study day. The yoghurt
was prepared on-site on the morning of the study. The sub-
jects were given 5min to consume the preload; 30min fol-
lowing the end of ingestion a ‘buffet-style’ selection of
cold food and drinks, containing palatable items in
excess of what the subject would normally eat, was
placed in the test room. The subjects had free access to
the buffet meal and energy intake was quantiﬁed hourly
for 8h (Beckoff et al. 2001). The subjects were blinded
to the time of day, and external cues that might affect appe-
tite, for example radio, were minimised. Venous blood
samples for the measurement of plasma CCK were taken
at baseline and every 10min for 30min following ingestion
of the preload and then every 30min between 0 and
510min. Following each study day, the subjects were
asked to maintain a diary to document the timing of all
bowel motions and any side effects, and to perform a 3d
faecal fat collection. The completeness of the faecal fat
collection was assessed using the diary.
Total energy intake was then calculated using commer-
cially available software (Foodworks version 2.10; Xyris
Software (Australia) Pty Ltd, Highgate Hill, QLD,
Australia) (MacIntosh et al. 2001a). Serum CCK was deter-
mined by a radioimmunoassay as previously described
(MacIntosh et al. 2001b). Faecal fat was expressed as g
stearic acid and the difference in fat excreted in the
faeces following orlistat compared with control was
expressed in kJ. Total (calculated) energy intake (kJ) was
derived for each study day as energy intake from the pre-
load (allowing for faecal fat excretion) in addition to
energy intake for the remainder of the day (8h). Energy
intake and plasma CCK levels at 20min (when maximum
plasma levels were expected following a fat preload
(Feinle et al. 2003)) were analysed using Student’s paired
t test. Plasma CCK from 0 to 30min was analysed using
repeated measures ANOVA, and the areas under the
curve from 0 to 510min were compared. Data are shown
as mean values and standard errors of the mean and a P
value ,0·05 was considered statistically signiﬁcant.
Results
The study protocol was well tolerated. Of the fourteen sub-
jects, twelve completed faecal fat collections on both days,
and plasma samples from one subject were unsuitable for
analysis for one study day.
Energy intake for the remainder of the day was greater
following orlistat (10276 (SEM 933) kJ) v. control (9449
(SEM 827) kJ) (P¼0·02; Fig. 1); there was no difference
in the proportion of each macronutrient consumed (data
not shown). In all cases fat excretion was greater after orli-
stat (1017 (SEM 168) kJ) v. control (484 (SEM 90) kJ)
(P¼0·004). There was no difference in total (calculated)
energy intake after orlistat (11282 (SEM 1045) kJ) v. con-
trol (10868 (SEM 857) kJ). Plasma CCK increased after
both preloads (P¼0·0001). Plasma CCK at 20min was
less after orlistat (4·1 (SEM 0·9) pmol/l) v. control
(5·3 (SEM 0·9) pmol/l) (P¼0·028), but there was no differ-
ence in the area under the curve from 0 to 510min after
orlistat (3856 (SEM 527) min £ pmol/l) v. control (3801
(SEM 389) min £ pmol/l).
Mild side effects were reported by eight subjects, all fol-
lowing orlistat and occurring within 24h of the completion
of the study; these ranged from abdominal discomfort (two
subjects) and ﬂatulence (four subjects) to loose, oily bowel
motions (ﬁve subjects). Only one subject reported side
effects (loose bowel motion) 6h following the ingestion
of orlistat.
Fig. 1. Energy intake at the buffet meal (0–480min) following
ingestion of a high-fat yoghurt preload with no orlistat (A; control) or
120mg orlistat (B). Data are mean values, with the standard errors
of the mean represented by vertical bars. * Mean value was signiﬁ-
cantly different from that of the control group (P¼0·02).
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The results of the present study demonstrate in healthy sub-
jects of normal body weight that: (i) the acute inhibitory
effect of fat on subsequent energy intake and early
stimulation of plasma CCK are attenuated by orlistat;
(ii) the magnitude of this increase in energy intake approxi-
mates the additional energy lost as a result of fat
malabsorption.
The suppression of hunger and energy intake (as well as
slowing of gastric emptying) induced by fat is dependent
on small-intestinal feedback inhibition; the latter is
mediated by fatty acids with a chain length of more than
twelve C atoms, and not triacylglycerols (Meyer et al.
1998; Matzinger et al. 2000). Previous information relating
to the effect of orlistat on energy intake is limited; in most
published studies energy intake has not been formally
assessed (Hill et al. 1999), or the methodology used has
been suboptimal, by relying on self-reporting diet diaries
(Franson & Rossner, 2000). In a previous study (Feinle
et al. 2003) acute lipase inhibition with orlistat (120mg)
during an intraduodenal fat infusion was associated with
a signiﬁcant increase in energy intake assessed at a
buffet meal following the infusion; faecal fat excretion
was not measured. A standardised 3d faecal fat collection
was, however, performed in the present study, and
although this probably reﬂects food intake after, as well
as during, the study period, signiﬁcant differences in
faecal fat were observed. The present study provides infor-
mation about the acute effects of orlistat on energy intake
in a more realistic setting and using a high-fat preload. The
usual therapeutic dose of orlistat is 120mg three times
daily with meals (Hill et al. 1999); hence, it is possible
that effects on energy intake may be even greater than
those demonstrated. Energy compensation in response to
the enteral infusion of fat has been demonstrated pre-
viously (Shide et al. 1995) and in both the present study
and previously (Feinle et al. 2003) it has been demon-
strated that subjects compensate accurately for energy
lost through lipase inhibition by increasing their energy
intake accordingly.
There is evidence that CCK may play a role in mediating
the suppressive effects of fat on subsequent energy intake
(Matzinger et al. 2000). CCK concentrations were initially
slightly lower following orlistat, but there was no differ-
ence in the overall plasma CCK response. While it is inap-
propriate to attribute differences in food intake over 8h to
the observed suppression of CCK at 20min, it should be
recognised that mean energy intake was greater after orli-
stat which would have favoured an increased CCK
response. Hence, it is probable that there was relative sup-
pression of CCK release. It is also appropriate to note that
numerous peptides released from the gastrointestinal tract
apart from CCK probably contribute to the regulation of
appetite; for example, glucagon-like peptide-1 and peptide
Y-Y (Feinle et al. 2003).
It has been demonstrated that acute lipase inhibition
with orlistat attenuates the inhibitory effect of oral fat on
subsequent energy intake and the increase in energy
intake approximates the energy lost due to fat malabsorp-
tion. The observations are not surprising, although they
may have substantial implications for the use of orlistat
in the treatment of obesity. The present study has focused
on the effects of a single dose (120mg) of orlistat in subjects
of normal body weight on energy intake. The results may
appear in conﬂict with data demonstrating a small, but sig-
niﬁcant, weight loss in obese subjects taking orlistat on a
chronicbasis.However,itshouldberecognisedthathealthy,
normal-weight volunteers were studied who were allowed
ad libitum access to food; this contrasts to chronic studies
of the use of orlistat in obese patients and involving energy
restriction. In view of the present observations studies are
now indicated to evaluate the ‘chronic’ effects of orlistat
on appetite, particularly in obese subjects, that may poten-
tially contribute to the variable response to the drug.
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